Santiago Vazquez

Prof. Santiago Vazquez

Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Molecular Metabolism
Verified
Journal Article
Open access
MZMohammad Zarei
Mohammad Zarei
Emma BarrosoEmma Barroso
Emma Barroso
XPXavier Palomer
Xavier Palomer
JDJianli Dai
Jianli Dai
PRPatricia Rada
Patricia Rada
Manuel Vazquez-CarreraManuel Vazquez-Carrera
Manuel Vazquez-Carrera
The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)β/δ and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. Studies were conducted in wild-type and Pparβ/δ-null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver biopsies from control subjects and patients with moderate and severe hepatic steatosis. Increased VLDLR levels were observed in liver of Pparβ/δ-null mice and in Pparβ/δ-knocked down mouse primary hepatocytes through mechanisms involving the heme-regulated eukaryotic translation initiation factor 2α (eIF2α) kinase (HRI), activating transcription factor (ATF) 4 and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARβ/δ mRNA abundance and DNA-binding activity compared with control subjects. Overall, these findings provide new mechanisms by which PPARβ/δ and FGF21 regulate VLDLR levels and influence hepatic steatosis development.

2 June 2020 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
Christian Griñán-FerréChristian Griñán-Ferré
Christian Griñán-Ferré
SCSandra Codony
Sandra Codony
EBEugènia Pujol Bech
Eugènia Pujol Bech
JYJun Yang
Jun Yang
RLRosana Leiva
Rosana Leiva
CGCarles Galdeano
Carles Galdeano

1 May 2005 in Tetrahedron
Verified
Journal Article
Closed access
Santiago VazquezSantiago Vazquez
Santiago Vazquez
PCPelayo Camps
Pelayo Camps

4 December 2019 in Aging
Verified
Journal Article
Open access
Christian Griñán-FerréChristian Griñán-Ferré
Christian Griñán-Ferré
Laura Marsal GarcíaLaura Marsal García
Laura Marsal García
ABAina Bellver-Sanchis
Aina Bellver-Sanchis
SKShukkoor Muhammed Kondengaden
Shukkoor Muhammed Kondengaden
RTRavi Chakra Turga
Ravi Chakra Turga
Merce PallasMerce Pallas
Merce Pallas
The implication of epigenetic mechanisms in Alzheimer's disease (AD) has been demonstrated in several studies. UNC0642, a specific and potent inhibitor of methyltransferase activity G9a/GLP (G9a-like) complex, was evaluated in the 5XFAD mouse model. UNC0642 treatment rescued 5XFAD cognition impairment, reduced DNA-methylation (5-mC), increased hydroxymethylation (5-hmC), and decreased the di-methylation of lysine 9 of histone H3 (H3K9me2) levels in the hippocampus. Increases in the Nuclear Factor erythroid-2-Related Factor 2 (NRF2), Heme oxygenase decycling 1 (Hmox1) gene expression, and diminution in Reactive Oxygen Species (ROS) were also reported. Moreover, neuroinflammatory markers, such as Interleukin 6 (Il-6), Tumor necrosis factor-alpha (Tnf-α) gene expression, and Glial fibrillary acidic protein (GFAP) immunofluorescence were reduced by UNC0642 treatment. An increase in Nerve growth factor (Ngf), Nerve growth factor inducible (Vgf) gene expression, Brain-derived neurotrophic factor (BDNF), and Synaptophysin (SYN) were found after UNC0642 treatment. Importantly, a reduction in β-amyloid plaques was also observed. In conclusion, our work demonstrates that the inhibition of the G9a/GLP complex by UNC0642 delivered significant neuroprotective effects in 5XFAD mice, point out G9a/GLP as a new target for AD.

5 April 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MDMaría D. Duque
María D. Duque
CMChunlong Ma
Chunlong Ma
ETEva Torres
Eva Torres
JWJun Wang
Jun Wang
LNLieve Naesens
Lieve Naesens
Santiago VazquezSantiago Vazquez
Santiago Vazquez

30 June 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MRMatias Rey-Carrizo
Matias Rey-Carrizo
Marta Barniol-XicotaMarta Barniol-Xicota
Marta Barniol-Xicota
CMChunlong Ma
Chunlong Ma
MFMarta Frigolé-Vivas
Marta Frigolé-Vivas
ETEva Torres
Eva Torres
Santiago VazquezSantiago Vazquez
Santiago Vazquez
Amantadine inhibits the M2 proton channel of influenza A virus, yet most of the currently circulating strains of the virus carry mutations in the M2 protein that render the virus amantadine-resistant. While most of the research on novel amantadine analogues has revolved around the synthesis of novel adamantane derivatives, we have recently found that other polycyclic scaffolds effectively block the M2 proton channel, including amantadine-resistant mutant channels. In this work, we have synthesized and characterized a series of pyrrolidine derivatives designed as analogues of amantadine. Inhibition of the wild-type M2 channel and the A/M2-S31N, A/M2-V27A, and A/M2-L26F mutant forms of the channel were measured in Xenopus oocytes using two-electrode voltage clamp assays. Most of the novel compounds inhibited the wild-type ion channel in the low micromolar range. Of note, two of the compounds inhibited the amantadine-resistant A/M2-V27A and A/M2-L26F mutant ion channels with submicromolar and low micromolar IC50, respectively. None of the compounds was found to inhibit the S31N mutant ion channel.